STI tests could boost HIV prevention in african women
NCT ID NCT06743204
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 34 times
Summary
This study in Uganda tests whether adding lab tests for sexually transmitted infections (STIs) to standard HIV risk screening helps more women start and continue taking PrEP, a daily pill that prevents HIV. About 4,500 HIV-negative women aged 15-39 will be randomly assigned to either standard screening alone or standard screening plus STI testing. The goal is to see if knowing they have an STI makes women more aware of their HIV risk and more likely to use PrEP consistently.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Rakai Health Sciences Program
RECRUITINGKalisizo, Uganda
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
STI diagnostic testing for chlamydia, gonorrhea, trichomonas, and syphilis
What this could lead to
If successful, this approach could help more women at high risk for HIV get on PrEP and stay on it, reducing new HIV infections in Africa.
What could go wrong
This is an early-stage implementation trial, so results may not apply broadly. Adding STI testing may not significantly improve PrEP use, and cost or logistics could limit real-world adoption.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.